Effect of H2 inhalation therapy on early recurrence after atrial fibrillation ablation.

Prior treatment

• Persons referred to in Articles L1121-5 to L1121-8 of the CSP and Articles 31 to 35 of Regulation 536/2014 (corresponds to all protected persons: pregnant women, women in labor, breastfeeding mothers, persons deprived of their liberty by judicial or administrative decision, persons receiving psychiatric care pursuant to Articles L. 3212-1 and L. 3213-1 who are not covered by the provisions of Article L. 1121-8, persons admitted to a health or social care institution for purposes other than research, minors, persons subject to legal protection measures or unable to give their consent).

Other illness

• Have a history of AF ablation.

Age

• Be over 80 years of age

Other

• Personnel with a hierarchical relationship with the principal investigator
• Have a left atrial diameter ≥ 50 mm on TEE.
• Radiofrequency ablation.
• Patient undergoing long-term anti-inflammatory treatment.
• Patients with gas administration equipment (CPAP, NIV, etc.)
• Women of childbearing potential
• Uncooperative patients
• During exclusion period from another study

• Be over 18 years of age
• Have paroxysmal or persistent AF with symptoms lasting less than 6 months
• Be a candidate for first-time AF ablation (cryoablation, electroporation)
• Understand and agree to comply with the study procedures
• Have a smartphone
• Be enrolled in a social security program or have similar rights
• Have signed the study consent form